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Accepted 3 May 2011; Published online 9 September 2011AbstractObjective: In some trials, the intervention is delivered to individuals in groups, for example, groups that exercise together. The group
structure of such trials has to be taken into consideration in the analysis and has an impact on the power of the trial. Our aim was to provide
optimal methods for the design and analysis of such trials.
Study Design and Setting: We described various treatment allocation methods and presented a new allocation algorithm: optimal
batchwise minimization (OBM). We carried out a simulation study to evaluate the performance of unrestricted randomization, stratification,
permuted block randomization, deterministic minimization, and OBM. Furthermore, we described appropriate analysis methods and
derived a formula to calculate the study size.
Results: Stratification, deterministic minimization, and OBM had considerably less risk of imbalance than unrestricted randomization
and permuted block randomization. Furthermore, OBM led to unpredictable treatment allocation. The sample size calculation and the anal-
ysis of the study must be based on a multilevel model that takes the group structure of the trial into account.
Conclusion: Trials evaluating interventions that are carried out in subsequent groups require adapted treatment allocation, power cal-
culation, and analysis methods. From the perspective of obtaining overall balance, we conclude that minimization is the method of choice.
When the number of prognostic factors is low, stratification is an excellent alternative. OBM leads to better balance within the batches, but
it is more complicated. It is probably most worthwhile in trials with many prognostic factors. From the perspective of predictability, a treat-
ment allocation method, such as OBM, that allocates several subjects at the same time, is superior to other methods because it leads to the
lowest possible predictability.
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Open access under the Elsevier OA license.1. Introduction
Group interventions, whether self-help or professionally
conducted, are popular among patients and caregivers.
They are used in the context of various, mainly, chronic dis-
eases; for example, exercise groups for obese teenagers,
psychoeducational group interventions for the management
of psychiatric disorders, or support groups for informal
caregivers of elderly people with dementia [1e3]. Depend-
ing on the group’s purpose and needs, a group intervention
will be either open or closed. Open groups run on an ongo-
ing basis and new members can join at any time during the
group’s existence, whereas closed groups do not allow new-
comers to join once the group has commenced. In this arti-
cle, we restrict ourselves to closed groups.* Corresponding author. Tel.: þ31-24-3616772; fax: þ31-24-3617408.
E-mail address: m.faes@ger.umcn.nl (M.C. Faes).
0895-4356  2012 Elsevier Inc.
doi: 10.1016/j.jclinepi.2011.05.007
Open access under the Elsevier OA license.Group interventions often help participants by providing
an opportunity for social comparison [4]. The groups may
include subjects that differ on factors affecting social com-
parison, such as stages of disease or capability to express
feelings and emotions [4]. This implies that the composi-
tion of a group may have a substantial impact on the out-
come. A group with a majority of women, for example,
may interact and react differently than a group with mainly
men [5]. Not only are the subjects in a group likely to in-
fluence each other, but the leader, instructor, or therapist
also may have an impact. This leads to a correlation within
the groups and to extra variation of the treatment outcome
between groups. These factors have to be taken into ac-
count in the statistical analysis and have consequences for
the size of the trial, (see Sections 8 and 9). When the treat-
ment outcome varies between groups, this increases the
between-group variance and therefore decreases the power
of the trial. To reduce the differences between the groups, it
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- Trials that evaluate an intervention that is delivered
to individuals in groups require adapted treatment
allocation, analysis, and study size calculation
methods.
- Treatment allocation should be carried out at the
same time for all subjects that qualify for a certain
group.
- Optimal batchwise minimization optimizes the bal-
ance of treatments among prognostic factors and
makes treatment allocation unpredictable.
- For the analysis, a multilevel model is required,
with group as random factor and batch as fixed
factor.
- The group structure of these trials necessitates
a larger sample size.
may be useful to use treatment allocation methods that at-
tempt to balance prognostic factors. Stratification and min-
imization are the commonly used methods to reduce
imbalance on prognostic factors [6]. We describe the per-
formance of these methods when used in an intervention
trial with a closed group format in Sections 6 and 7. It is
important that prognostic factors are balanced over the
treatment arms at the end of the trial because imbalance
on prognostic factors undermines the credibility of the trial
[7e9]. Furthermore, it also decreases the power of the trial
[6,10]. Minimization can handle more prognostic factors
than stratification, but a disadvantage of minimization isFig. 1. Diagram of the design of a trial with group treatments in both arms (
(b). Each time a group treatment starts in one of the treatment arms a corre
treatment (a) or an individual treatment (b). These subjects constitute a bathat in certain circumstances it leads to predictability of
the next allocation (see Section 3).
However, when a treatment is given in a closed group
format, a group can only start when the complete group
has been enrolled. It is important to have parallel treatments
in a clinical trialdideally groups should run simulta-
neously and should start in pairs, one in each treatment
arm. In practice, this means that treatment allocation needs
to be postponed till sufficient participants for two groups
have been enrolled. In fact, postponement of the allocation
is preferable because it may reduce loss to follow up after
allocation. When treatment allocation takes place for all
participants of two groups at the same time, it is possible
to further optimize the balance and to make the allocation
unpredictable. For this purpose, we developed an allocation
method called optimal batchwise minimization (OBM). We
describe the method in Section 4 and show to what extent it
improves balance in Sections 6 and 7.2. Terminology and examples
Fig. 1a shows the design of a trial that compares two
treatments that are given in closed groups, for example,
a trial that compares two programs aimed at supporting
juveniles with cancer. In treatment arm A, groups of 10
juveniles sit together and exchange experiences and get
advice. In treatment B, not only the juveniles, but also their
parents exchange experiences and get advice. The treat-
ments are given in closed groups, so a group cannot start
until all participants have been enrolled in the study. In this
example, this implies that each time that a batch of 20
youths has been enrolled, two groups of 10 can be formed
(one in each treatment arm). The illustration of the design
(Fig. 1) shows each batch enclosed by dotted lines, anda) and a trial that compares a group treatment to individual treatment
sponding number of subjects in the other arm receives either a group
tch, and the study consists of a number of such batches.
140 M.C. Faes et al. / Journal of Clinical Epidemiology 65 (2012) 138e146the groups nested within those batches are shown as gray
squares. The group numbers, shown between brackets, will
be discussed in Section 8.
Fig. 1b shows the design of a trial that compares a group
treatment (arm A) to an individual treatment (arm B). We
are currently performing such a trial. It evaluates a fall pre-
vention program aimed at reducing falls and fear of falling
in community-dwelling frail older patients who have expe-
rienced a recent fall. The program consists of a closed
group intervention of 10 two-hour sessions with both phys-
ical and psychological components. Balance and gait exer-
cises are practiced under the guidance of a physiotherapist,
and a psychologist discusses feelings, emotions, and expe-
riences associated with falls. Half of the patients receives
the intervention in a closed group format, and the other half
receives usual individual care (controls). To ensure patient
safety, each group consists of only six patients. Therefore,
the batch size is 12. Each batch consists of six patients in
treatment arm A and six patients in treatment arm B. The
patients in treatment arm A receive the intervention as
a group, whereas the patients in treatment arm B receive
usual (i.e., individual) treatment and are therefore not part
of a group and have no interaction with each other or with
an instructor. We have attempted to illustrate this design in
Fig. 1b by showing the intervention group (arm A) in an un-
divided square and the control group (arm B) in a subdi-
vided square in which each participant is represented by
a separate rectangle. The rectangles are intended to illus-
trate that the patients in arm B are treated individually.
As the fall prevention trial was fairly small, with 54 par-
ticipants per treatment arm, wewereworried that imbalances
on important baseline variables would occur despite random-
ization and that this would undermine the credibility of the
trial [7e9]. Hence we planned to carry out stratification or
minimization to minimize the risk of imbalances. In the next
section, we will describe these methods in detail.
We selected baseline variables that could have an impact
on the outcome of the study (prognostic factors) based on
results of previous research. Earlier studies demonstrated
that cognitive impairment and female gender are risk fac-
tors for falling. Additionally, a history of falls and age were
known to be positively associated with falls [11,12]. We
therefore considered age, gender, mini-mental status exam-
ination (MMSE) score [13], and number of falls in the past
year as prognostic factors that should be balanced between
the two treatment arms. Each of these factors was dichoto-
mized, resulting in the following prognostic factors: gender
(man vs. woman), age (younger [80] vs. older [O80]),
cognitive status (low MMSE [15e23] vs. high MMSE
[24e30]), and number of falls in the past year (1 vs. O1).3. Existing treatment allocation methods
Various methods have been developed for treatment allo-
cation, as described below.3.1. Unrestricted randomization
In unrestricted randomization, allocation is based on
chance alone. In the case of two treatments with equal
allocation, every subject has a probability of 1/2 of receiv-
ing one or the other, so the chance of correctly guessing the
next allocation is 50%. Therefore, the predictability of the
treatment allocation is said to be 50%. However, unre-
stricted randomization may lead to an imbalance of prog-
nostic factors, and this may make the interpretation of the
results of the study difficult. Furthermore, such imbalance
may decrease the power of the trial [6,10].3.2. Randomization in permuted blocks
This randomization method [6] seems more suitable for
trials that evaluate closed group interventions, especially
when the size of the batch is used as block size. The pre-
dictability of the allocation for subjects that are enrolled
when a new block has just started is 50% but toward the
end of the block it may increase to 100% because if one
knows all previous allocations, the last allocation in the
block can perfectly be predicted. As is the case for unre-
stricted randomization, permuted block randomization also
can result in imbalances on prognostic factors.3.3. Stratified randomization
Stratified randomization [6] prevents imbalances, even
for combinations of prognostic factors. In the fall preven-
tion trial, for example, stratified randomization aims to
have balance for all possible combinations of the four prog-
nostic factors mentioned in Section 2. Each treatment arm
should have half of the women over 80 with low MMSE
and only one fall in the previous year. Likewise, the women
over 80 with low MMSE and repeated falls in the previous
year also should be equally distributed over the two treat-
ment arms, and so forth. Balance is sought for all possible
combinations of the prognostic factors. With four prognos-
tic factors, the number of combinations is 245 16, and this
divides the trial population into 16 different strata. When
the number of factors increases, the number of strata in-
creases exponentially, and this limits the number of vari-
ables that can be stratified for [8,14]. The predictability
of the allocation with stratification is 50%.3.4. Minimization
Minimization [6,15] makes it possible to balance treat-
ment allocations for more prognostic factors. It is not aimed
at balance within all strata, but at marginal balance. In the
falls prevention trial, it seeks to arrange that each treatment
arm has half of the women, half of the men, half of the over
80, half of the under 80, and so forth. It may still be the
case, however, that the women over 80, men over 80,
men under 80, and so forth are not equally divided over
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balance of the prognostic factors within the strata.
Minimization can be carried out in two ways: deter-
ministically or with a random component. In determinis-
tic minimization, each subsequent subject is allocated to
the treatment that leads to the least imbalance. Determin-
istic minimization has the disadvantage that someone
with knowledge of all previous allocations can predict
the next allocation (high predictability) [10,15,16], and
this may be an issue when all patients are enrolled or
treated by a single investigator. When more investigators
are involved that do not exchange information, predict-
ability drops considerably. In minimization with a random
component, each subsequent subject is allocated to a treat-
ment such that there is a certain probability that the al-
location will result in the least imbalance, for example,
with 75% chance [6,15]. If someone knows all previous
allocations, the predictability is 75%. Because there is
a 25% chance that an allocation will worsen the balance,
minimization with a random component has a higher risk
of imbalance over the treatment arms than deterministic
minimization.4. Optimal batchwise minimization
The methods discussed above are all based on sequential
treatment allocation: each time a subject is enrolled, a treat-
ment is allocated. In trials that evaluate closed group inter-
ventions, however, the group treatment will not start before
a sufficient number of patients for a complete group is
available, so it is possible to wait and carry out the treat-
ment allocation once a whole batch is enrolled. In this sit-
uation, OBM can be used.
OBM is based on an algorithm that consists of three
steps that are carried out for each consecutive batch of
newly enrolled subjects:
1. Calculate the Sum of the Squared Factor Class Imbal-
ances (SSFCI) for all possible allocations of the newly
enrolled subjects [6,15,17e19].We use the fall preven-
tion study to illustrate the calculation of the SSFCI.
Each prognostic factor had two classes: man vs. woman,
younger (80) vs. older (O80), low MMSE (15e23) vs.
high MMSE (24e30), and one fall vs. recurrent falls in
the past 12 months. Diffman denotes the difference between
the numbers of men in the treatment arms. Similarly,
diffwoman, diffyoung, diffold, difflowMMSE, diffhighMMSE,
diffonefall, and diffrecurrentfalls denote the (absolute) differ-
ences between the numbers in the treatment arms for the
other factor classes.The SSFCI is then computed for each
possible allocation as:SSFCI5diff 2manþ diff 2womanþ diff 2youngþ diff 2old þ diff 2lowMMSE
þ diff 2highMMSE þ diff 2onefall þ diff 2recurrentfalls2. List all allocations with minimum SSFCI.
3. Randomly select one of the allocations with mini-
mum SSFCI.
The algorithm is repeated for the complete enrollment of
each batch. In the Appendix, we present a SAS program
and an R program that can be used to carry out OBM (see
Appendix on the journal’s Web site at www.elsevier.com).5. Evaluation of treatment allocation methods
We carried out a simulation study to compare the perfor-
mance of unrestricted randomization, randomization in per-
muted blocks, stratification, deterministic minimization,
and OBM. Our aim was to show that stratification, minimi-
zation, and OBM lead to substantially better balance than
randomization in permuted blocks. We further aimed to
evaluate the additional improvement of OBM vs.
minimization.
The simulated trials differed in batch size, trial size, and
the number of factors for which balance was sought. Trials
with batches of 12 subjects had a total sample size of 48,
96, or 192 subjects. The trials with batches of 24 subjects
had a total sample size of 96 or 192 subjects. For each sim-
ulated trial, balance was sought for 3, 6, or 12 factors with
two classes per factor. We generated 1,00,000 trials for each
combination of trial size, batch size, and number of factors.
We carried out the five allocation methods in each trial and
calculated the maximal imbalance (MaxI) of the trial, the
maximal batch imbalance (MaxBatchI), and the mean batch
imbalance (MeanBatchI) as measures of performance for
each method, as described below:
1. The MaxI is the maximum of the imbalances on the
predictors in the trial [16]. Suppose that the treatment
allocation in the fall prevention trial results in four
more men in the intervention treatment arm than
the control arm. Furthermore, the treatment arm has
six more women, but four fewer older patients, two
fewer patients with low MMSE, and two fewer pa-
tients with high MMSE, whereas the patients with
and without recurrent falls and the younger patients
are equally distributed over treatment arms. Then
the imbalances are 4, 6, 4, 2, 2, 0, and 0, and MaxI
is equal to the maximum imbalance of 6.
Of course, the importance of the imbalance depends on
the size of the trial. A MaxI of six in a trial with two treat-
ment arms of 24 patients each is more substantial than the
same imbalance in a trial with 240 patients per treatment
arm. Hence, we will present the relative MaxI (RelMaxI)
by dividing the imbalance by the treatment arm size. For
6 of 24, the relative imbalance is 25%, whereas for 6 of
240, it is 2.5%. If all trial participants in a factor class were
in one treatment arm only, then the imbalance would be
100%.
Fig. 2. Box plots for the relative maximal imbalance (RelMaxI) when
the group size is 6 and the total number of subjects is 48. The bold
horizontal bars indicate the medians, the ends of the boxes indicate
the quartiles, the whiskers go up to the 5th and 95th percentiles,
and the triangles represent the maximum. For each combination of
number of factors and number of batches, the light gray, dark gray,
and white boxes correspond to OBM, deterministic minimization,
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ances in the batches. Suppose a trial has five batches
and the MaxI in the factors in those batches is 0, 2, 4,
0, and 1, then MaxBatchI is 4.
In the fall prevention trial, MaxBatchI is the maximum
of diffman,i, diffwoman,i, diffyoung,i, diffold,i, difflowMMSE,i,
diffhighMMSE,i, diffonefall,i, and diffrecurrentfalls,i over all
batches 1, 2,. , i,.. Diffman,i is the difference in number
of men between the treatment arms in batch i, diffwoman,i is
the difference in number of women, and so forth.
Again, the importance of the imbalance depends on the
batch size. Therefore, the relative MaxBatchI (RelMax-
BatchI) is equal to the MaxBatchI divided by the number
of participants in each treatment arm of the batch.
3. The MeanBatchI is the mean of all factor class im-
balances in all batches: MeanBatchI is the mean of
diffman,i, diffwoman,i, diffyoung,i, diffold,i, difflowMMSE,i,
diffhighMMSE,i, diffonefall,i, and diffrecurrentfalls,i over all
batches 1, 2, ., i, .. MeanBatchI is converted to
the relative MeanBatchI (RelMeanBatchI) in the
same way that MaxBatchI is converted to
RelMaxBatchI.and permuted block randomization, respectively.
Fig. 3. Box plots for the relative maximal imbalance (RelMaxI) when
the group size is 12. The bold horizontal bars indicate the medians,
the ends of the boxes indicate the quartiles, the whiskers go up to
the 5th and 95th percentiles, and the triangles represent the maxi-
mum. For each combination of number of factors and number of
batches, the light gray, dark gray, and white boxes correspond to
OBM, deterministic minimization, and permuted block randomiza-
tion, respectively.6. Results: overall imbalance at the end of the study
Fig. 2 shows box plots of the RelMaxIs that were found
in the simulated studies. For example, for studies with 48
patients and 3 prognostic factors, randomization led to
a median RelMaxI of 25% of the treatment arm size
(Fig. 2). So in half of the studies of this type, at least one
of the prognostic factors had an imbalance of 25% or more
at the end of the study, that is, 6 subjects out of 24. Simi-
larly, the lower and upper quartiles were 17% and 33%,
so there was a chance of 75% that the imbalance exceeded
17% of the treatment arm size for at least one of the prog-
nostic factors and a chance of 25% that it exceeded 33%.
The 95th percentile was 46%, so in 5% of the simulated tri-
als, the relative maximal imbalance exceeded 46% of the
treatment arm size, that is, 11 subjects. Finally, the maxi-
mum was 75%, so the imbalance never exceeded 75%
out of 24 patients, or 16 subjects.
Figures 2 and 3 illustrate that both minimization and
OBM substantially reduced the risk of imbalances at the
end of the study. When permuted block randomization
was used and the trials had 192 subjects and 3 prognostic
factors, the upper quartile of the RelMaxI was 24%, so
there was a 25% chance of imbalances exceeding 24%, that
is, an imbalance of 12 or more subjects. When the number
of factors was larger, or when the trials were smaller, the
upper quartiles were between 30% and 45%. The results
for randomization with blocks of various lengths were sim-
ilar to the results for unrestricted randomization (results not
shown).For minimization and OBM, the RelMaxI almost never
exceeded 20%. The difference between OBM and minimi-
zation was modest. The largest difference was observed
with 12 prognostic factors and a trial size of 48, when
the upper quartiles differed by approximately 5%.
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were similar to those for the upper quartiles. Stratification
was only practical for three prognostic factors (eight strata)
and led to similar results as minimization (not shown).Fig. 5. Box plots for the relative mean batch imbalance (RelMean-
BatchI) when the group size is 12 and the total number of subjects
is 192. The bold horizontal bars indicate the medians, the ends of
the boxes indicate the quartiles, the whiskers go up to the 5th and
95th percentiles, and the triangles represent the maximum. For each
combination of number of factors and number of batches, the light
gray, dark gray, and white boxes correspond to OBM, deterministic
minimization, and permuted block randomization, respectively.7. Results: imbalance in the batches
Figures 4e7 show box plots of the imbalance in the
batches resulting from OBM, deterministic minimization,
and randomization in permuted blocks. The RelMean-
BatchI for OBM never exceeded 20% for trials with batches
of 12 subjects (Fig. 4) and never exceeded 10% for trials
with batches of 24 subjects (Fig. 5). In general, the imbal-
ance observed with minimization was higher by a factor 1.3
when three factors were used and higher by a factor 1.7e2
for more than three factors. Imbalance remained below
30% in trials with batches of 12 subjects and did not exceed
20% for trials with batches of 24 subjects.
Figures 6 and 7 show the RelMaxBatchI. For trials with
up to 6 factors and batches of 12 or 24 subjects, the upper
quartiles of imbalance for OBM never exceeded 35% and
20%, respectively. For trials with 12 prognostic factors
and batches of 12, the upper quartiles of RelMaxBatchI
were between 35% and 50%. When the batch size was
24, the upper quartile was approximately 25%. For minimi-
zation, the upper quartiles were a factor 1.3e2 higher.
In all cases, permuted block randomization led to substan-
tially larger batch imbalance. The results for unrestricted
randomization were similar (not shown). Stratification was
only practical for three prognostic factors (eight strata) and
led to similar results as minimization (not shown). BecauseFig. 4. Box plots for the relative mean batch imbalance (RelMean-
BatchI) when the group size is 6. The bold horizontal bars indicate
the medians, the ends of the boxes indicate the quartiles, the whis-
kers go up to the 5th and 95th percentiles, and the triangles represent
the maximum. For each combination of number of factors and number
of batches, the light gray, dark gray, and white boxes correspond to
OBM, deterministic minimization, and permuted block randomiza-
tion, respectively.the number of batches did not affect the outcome, we did
not show the results for trials with 8 batches of 12 subjects.8. Analysis methods
As we explained in the introduction, the group structure
of the intervention needs to be taken into account in theFig. 6. Box plots for relative maximal batch imbalance (RelMax-
BatchI) when the group size is 6. The bold horizontal bars indicate
the medians, the ends of the boxes indicate the quartiles, the whis-
kers go up to the 5th and 95th percentiles, and the triangles represent
the maximum. For each combination of number of factors and number
of batches, the light gray, dark gray, and white boxes correspond to
OBM, deterministic minimization, and permuted block randomiza-
tion, respectively.
Fig. 7. Box plots for the relative maximal batch imbalance (RelMax-
BatchI) when the group size is 12. The bold horizontal bars indicate
the medians, the ends of the boxes indicate the quartiles, the whis-
kers go up to the 5th and 95th percentiles, and the triangles represent
the maximum. For each combination of number of factors and number
of batches, the light gray, dark gray, and white boxes correspond to
OBM, deterministic minimization, and permuted block randomiza-
tion, respectively.
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patients in a given batch have the same batch number. For
example, there were 12 patients per batch in the fall preven-
tion trial, so all 12 patients in a given batch would have the
same batch number. Fig. 1 gives an example of the batch
numbers. The numbers can be arbitrary, as long as different
batches have different numbers.
Furthermore, a ‘‘group’’ variable is required. In the trial
that evaluated support to juvenileswith cancer (seeSection2),
every youth received treatment in a group, and each of these
groups should have its own unique number. In Fig. 1a, group
numbers are shown between brackets. The group numbers
are arbitrary, as long as different groups have different
numbers.
When the treatment is given in a group format in only
one arm of the trial, such as in the fall prevention trial,
every subject in the other arm constitutes his own group
and must be assigned his own unique group number.
Fig. 1a illustrates this. Patients in treatment arm A received
the intervention in a group format, so all six patients in
a given group have the same group number. Patients in
treatment arm B received individual treatment, and so every
patient has his own group number.
If unrestricted or permuted block randomization is used to
allocate the treatments, the outcome of the trial should be
evaluated in a mixed model (multilevel model) with group
as a random factor and treatment and batch as fixed factors.
If stratification, minimization, or OBM are used for treat-
ment allocation, the prognostic factors should be included
as additional fixed variables. Variables that are expected to
correlate with the outcome of the study should always beincluded as variables in the analysis because they will in-
crease the power of the analysis, even if they are not used
as actors in the stratification, minimization, or OBM [20,21].
When stratification, minimization, or randomization was
used in the fall prevention trial, the fixed variables would be
treatment arm, batch, gender, history of falls, age, and
MMSE. ‘‘Group’’ would be the random factor.9. Trial size
The trial size for a study of an intervention that is deliv-
ered to individuals in groups is most easily calculated in
a stepwise fashion. First, calculate the number of subjects
that would be required if the treatment arm ratio were 1:1
and a t-test were carried out for the analysis. Next, if both
treatments are given in a group format, the actual study size
can then be calculated by multiplying this number by the
design factor:1þ lAðkB 1ÞICCþ lAðkB 1ÞICC ð1Þ
Here, lA and lB are the proportion of the subjects that
are in arms A and B, respectively. The group sizes in the
two arms of the trial are kA and kB, respectively. ICC is
the intraclass correlation, that is, the quotient of the
between-batch variance and the total variance. The deriva-
tion of the formula is shown in the Appendix (see Appendix
on the journal’s Web site at www.elsevier.com).
When group B has no closed groups, as in the fall pre-
vention trial, kB5 1. In that case, the formula simplifies to:1þ lBðkA 1ÞICC ð2Þ
As can be seen from the formulas, the group structure
leads to an increase in trial size. Adjustment for baseline
covariates may then allow for a reduction in trial size by
a factor 1 r2, where r is the correlation between the base-
line and follow-up measurements [20].
In the falls trial, for example, the fall rate was expected
to drop from 0.5 to 0.3 per year, with a standard deviation
of 0.4. Based on a t-test, a total of 128 patients would then
be required for 80% power and a two-sided testing at
a5 0.05. The ICC was thought to be 0.05. When we
now use formula (2), with kA5 6 and lB5 0.5, we find that
the study should have [1þ 0.5(6 1)0.05]1285 144 par-
ticipants. Furthermore, we expected a correlation of 0.5
between the number of falls before and after start of treat-
ment, and so the inclusion of the number of falls before
treatment as a covariate resulted in a reduction of trial size
to a trial size of at least (1 0.52)1445 108 subjects, that
is, nine batches.
If the treatment ratio were six to four, so that each batch
had 10 subjects of which six received the group treatment
and four received individual treatment, lB would be 0.4. For-
mula (2) would then lead to a trial of [1þ 0.4(6 1)0.05]
1285 141 subjects. Adjustment for the number of falls be-
fore start of the treatment leads to (1 0.52)1415 106
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lead to a trial of 11 batches, with a total of 110 subjects.10. Discussion and conclusion
We described methods for the design, the analysis, and
the sample size determination of trials evaluating interven-
tions that are delivered to individuals in closed groups. The
group structure of the trial requires multilevel analysis and
has an impact on the power of the trial.
Furthermore, we developed and described OBM: a new
allocation method for trials evaluating interventions that are
delivered to individuals in groups that are subsequently as-
signed to randomization. We compared the performance of
unrestricted randomization, permuted block randomization,
stratification, deterministic minimization, and OBM and
found that the latter two methods have considerably less
risk of imbalance than unrestricted randomization and per-
muted block randomization. When stratification is feasible,
that is, when the number of factors does not exceed three,
also stratification has considerably less risk of imbalance
than unrestricted randomization and permuted block ran-
domization. We used the MaxI to quantify the imbalance
at the study level. As we mentioned before, a large imbal-
ance on one or more prognostic factors, that is, a large
MaxI, may lead to questions about the interpretation of
the results of the study. Therefore, MaxI is a suitable pri-
mary outcome measure to evaluate the performance of
the treatment allocation methods [7e9].
On the batch level, OBM leads to less imbalance than
minimization. However, the exact impact of the imbalance
is difficult to estimate. Although it has been speculated that
the composition of a group may have a substantial impact on
the outcome, to our knowledge there is no quantitative infor-
mation about the extent of the impact. Most likely it will vary
substantially, depending on the nature and the constitution of
the groups. Furthermore, between-group differences lead to
an increase of the variance and therefore decrease the power
of the trial, but it is difficult to quantify the strength of this
relationship. Most likely, the extra variance because of im-
balance is proportional to the size of the imbalances but
how large the impact is will depend on many factors, such
as the strength of the relation between the prognostic factors
and the outcome, the number of prognostic factors, the batch
size, and the correlation between those factors.
We have evaluated OBM in trials with up to 12 factors,
whereas the batch sizes were 12 or 24. The results mainly
depended on the number of factors, and a small additional
simulation also showed that for other batch sizes the imbal-
ance on the batch level was similar (results not shown).
We did not evaluate minimization with a random com-
ponent because the results would lie between permuted
block randomization and deterministic minimization.
When a random component is used, the chance that each
allocation is optimal has to be chosen beforehand and it
will lie between 50% and 100%. A chance of 50% wouldcorrespond to unrestricted randomization whereas a chance
of 100% would imply deterministic minimization. Accord-
ingly, the results for random component minimization lie
between those for randomization and deterministic mini-
mization. As the chance of an optimal allocation becomes
closer to 100%, the results are more similar to determinis-
tic minimization.
We used SSFCI for the minimization and OBM algo-
rithms because, to our knowledge, it is the most commonly
used method for minimization. Patient allocation based on
the SSFCI was originally developed by Taves, Pocock, and
Simon, is well known, and has shown excellent perfor-
mance [16e19,22e24]. However, other approaches also
could be used. For example, a weighted SSFCI would be
an option. In the fall prevention study, this would lead to
SSFCI5w1 diffman2 þw2 diffwoman2 þw3 diffyoung2 þ
w4  diffold2 þw5  difflowMMSE2 þw6  diffhighMMSE2 þ
w7 diffonefall2 þw8 diffrecurrentfalls2 . The weights w1, w2,
w3, . reflect the relative importance of the factors clas-
ses. In principle, all approaches that have been developed
for minimization [6,10,15] can be used for OBM.
From the perspective of obtaining overall balance, we
conclude that minimization is the method of choice. When
the number of prognostic factors is low, stratification is an
excellent alternative. OBM leads to better balance within
the batches, but it is more complicated. It is probably most
worthwhile in trials with many prognostic factors. From the
perspective of predictability, a treatment allocation method,
such as OBM, that allocates several subjects at the same
time, is superior to other methods because it leads to the
lowest possible predictability.Acknowledgments
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